Citi Places WUXI APPTEC on 90-Day Upside Catalyst Watch with Target Price of HKD142
Citi Research Report: Citi has included WUXI APPTEC in its 90-day upside catalyst watch, anticipating optimistic management guidance for 2026 performance in the upcoming results report in March.
Market Performance: WUXI APPTEC's stock has seen a short selling of $73.76M with a ratio of 21.151%, reflecting market activity and investor sentiment.
Analyst Ratings: Citi has assigned a Buy rating to WUXI APPTEC with a target price of HKD142, citing attractive valuation as a key factor.
M Stanley's Position: M Stanley continues to list WUXI APPTEC as a top pick for 2026, projecting a significant earnings surge in 2025.
Trade with 70% Backtested Accuracy
Analyst Views on 02359
About the author


Chinese Internet Healthcare Sector Growth: The sector is evolving with increased AI innovation from tech giants and support from national policies, such as Beijing's online consultation pilot program, despite profitability challenges.
Stock Recommendations: UOB Kay Hian maintains a positive outlook on companies like ALI HEALTH and PA GOODDOCTOR, projecting significant revenue growth driven by AI and synergies with major partners.
Top Picks in Healthcare: UOB Kay Hian's top stock picks include BEONE MEDICINES, INNOVENT BIO, and HANSOH PHARMA, highlighting their potential for growth in the Chinese healthcare market.
Investment Ratings: Various companies in the sector have received investment ratings, with several being rated as "Buy," indicating strong confidence in their future performance.

Market Performance: The Hang Seng Index (HSI) fell by 233 points (0.9%) to close at 27,032, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines.
Active Heavyweights: Major stocks like Meituan, Tencent, and Xiaomi saw significant drops, with Meituan down 4.5% and Tencent down 2.3%, amidst high short selling activity.
Notable Movers: Bud APAC and Lenovo Group faced substantial losses, with Bud APAC down 5.2%, while Zijin Mining and PICC P&C were among the few gainers, with Zijin Mining up 3.4%.
High Performers: Unisound and Guofuhee experienced remarkable gains, with Unisound rising by 16.8%, indicating strong market interest in these stocks.

Market Performance: Hong Kong stocks faced a decline, with the HSI dropping 242 points (0.9%) to 27,023, while the HSCEI and HSTECH also fell by nearly 1% and 1.7%, respectively.
Tech Stocks Struggles: Major tech companies like NTES, BABA, and TENCENT saw significant drops in their share prices, with NTES down 3.8% and BABA down 2.1%, amid disappointing earnings reports and ongoing investment strategies.
Chinese Developers' Gains: Some Chinese developers, including CHINA VANKE and RONSHINECHINA, experienced gains due to reports of a potential RMB80 billion rescue package from the Shenzhen municipal government.
WUXI APPTEC's Success: WUXI APPTEC emerged as the best-performing blue chip, rising nearly 4% after Nomura raised its revenue expectations and target price, indicating strong future performance.

Market Performance: The Hang Seng Index (HSI) fell by 242 points (0.9%) to 27,023, while the Hang Seng Tech Index (HSTI) and the Hang Seng China Enterprises Index (HSCEI) also experienced declines of 1.7% and 1.0%, respectively.
Active Heavyweights: Major stocks like Meituan, Tencent, Alibaba, and Xiaomi saw significant drops, with Meituan down 4.2% and Tencent down 2.6%, amidst high short selling activity.
Notable Movers: Wuxi AppTec and Wuxi Bio both hit new highs, increasing by 3.9% and 3.7%, respectively, while Bud APAC and Trip.com saw declines of 5% and 4.3%.
Short Selling Trends: High short selling ratios were observed across various stocks, with NetEase Music experiencing the largest drop of 11.9%, while Fit Hon Teng and COSCO Ship Energy saw substantial gains of over 10%.

Positive Profit Alert: WUXI APPTEC has issued a profit alert estimating a 9.2% increase in revenue and a 142% increase in net profit for Q4 2025, reaching RMB11.7 billion and RMB7.1 billion, respectively.
FY26 Revenue Forecast: For FY26, WUXI APPTEC's revenue is expected to grow by 16% YoY to RMB52.6 billion, surpassing market expectations, while earnings are projected to rise by 3% YoY to RMB19.6 billion.
Target Price Increase: Nomura has raised WUXI APPTEC's target price from HKD132.8 to HKD157.07 and maintains a Buy rating on the stock.
Market Context: The healthcare sector in China is increasingly relying on data and earnings visibility, with a positive outlook for CDMO firms, according to G Sachs.
Market Performance: The HSI rose by 155 points (0.6%) to close at 27,183, with a total market turnover of HKD234.04 billion. The HSCEI and HSTECH also saw gains, closing at 9,242 and 5,451 respectively.
Tech Stock Movements: Major tech stocks like TENCENT and MEITUAN-W experienced declines of 1.6% and 2.5%, while KUAISHOU-W, JD-SW, and BABA-W saw increases between 1.6% and 1.9%.
AI and Pharma Stocks Surge: AI stocks such as UNISOUND and INSILICO rose significantly, with KNOWLEDGE ATLAS jumping 14.8% after JPMorgan initiated coverage. Pharma stocks also performed well, with CSPC PHARMA and INNOVENT BIO gaining between 4.7% and 5.5%.
Chip Sector Performance: SMIC gained 1.7%, while HUA HONG SEMI dipped 1.2%. Other chip-related stocks like INNOSCIENCE and BIREN TECH saw notable increases, with INNOSCIENCE rising 6.9%.





